Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.

@article{Saglio2010DasatinibII,
  title={Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.},
  author={Giuseppe Saglio and Andreas Hochhaus and Yeow Tee Goh and Tamas Masszi and Ricardo Pasquini and F r{\'e}d{\'e}ric Maloisel and Philipp Erben and J. C. Gal{\'a}n Cort{\'e}s and Ronald L. Paquette and Mary Brigid Bradley-Garelik and Chao Zhu and Herv{\'e} Dombret},
  journal={Cancer},
  year={2010},
  volume={116 16},
  pages={3852-61}
}
BACKGROUND In a phase 3 study, the authors assessed the effects of dasatinib at doses of 140 mg once daily and 70 mg twice daily in patients who had either chronic myeloid leukemia (CML) in advanced phases or Philadelphia chromosome-positive acute lymphoblastic leukemia and were resistant or intolerant to imatinib. In the current report, the results for patients with CML in blast phase after 2 years of follow-up are reported. METHODS Patients were stratified according to whether they had CML… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

Similar Papers

Loading similar papers…